Key result
Drug-coated balloons were associated with a higher risk of 2-year device-oriented composite endpoint compared to drug-eluting stents in patients undergoing de novo, non-complex percutaneous coronary intervention, irrespective of pulse pressure levels.
Why the study?
The study investigated the impact of pulse pressure on long-term outcomes for patients treated with DCBs or DESs.
Does drug-coated balloon treatment reduce the 2-year device-oriented composite endpoint compared to drug-eluting stents in patients undergoing de novo, non-complex PCI across different pulse pressure levels?
RCT (n=2,272)
Open-label
1:1
Yes
Does drug-coated balloon treatment reduce the 2-year device-oriented composite endpoint compared to drug-eluting stents in patients undergoing de novo, non-complex PCI across different pulse pressure levels?
In patients undergoing de novo, non-complex PCI, drug-coated balloons are associated with a higher risk of device-oriented composite endpoints compared to drug-eluting stents, regardless of baseline pulse pressure.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Avoid DCB over DES in de novo non-complex PCI; challenges stent-free strategies irrespective of pulse pressure.
We investigate the impact of pulse pressure on long-term outcomes for patients treated with drug-coated balloons (DCBs) or drug-eluting stents (DESs). REC-CAGEFREE I was an investigator-initiated, non-inferiority trial conducted at 43 sites in China from Feb 5, 2021, to May 1, 2022, which randomized 2272 participants to DCB or DES treatment for de novo, non-complex lesions. In this post hoc analysis, participants were stratified into three groups based on pulse pressure tertiles (< 46, 46–60, and > 60 mmHg). The primary outcome was the 2-year device-oriented composite endpoint (DoCE), including cardiovascular death, target-vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization. 2272 participants were included in the analysis. At 2 years, DoCE occurred in 35/723 (4.9%), 37/896 (4.1%), and 38/653 (5.9%) of participants in the low, intermediate, and high pulse pressure groups, respectively. Compared to DES, DCB was associated with a higher risk of DoCE in the low (28/387 [7.3%] vs. 7/336 [2.1%], HRIPTW:3.82, 95%CI 1.64–8.87) and intermediate (24/436 [5.5%] vs. 13/460 [2.8%], HRIPTW: 2.09, 95%CI 1.05–4.15) pulse pressure groups. Among patients with high pulse pressure, the incidence of DoCE was numerically higher in the DCB group compared to the DES group (20/310 [6.5%] vs. 18/343 [5.3%], HRIPTW:1.34, 95%CI 0.70–2.55). No significant interaction was observed between pulse pressure and treatment (DCB or DES) regarding DoCE (Pinteraction = 0.124). DCB was associated with a higher risk of DoCE compared with DES in patients undergoing de novo, non-complex percutaneous coronary intervention, irrespective of pulse pressure levels. Registered on clinicaltrial.gov: NCT04561739.
Yang et al. (2026) conducted an RCT in De novo, non-complex coronary artery lesions (n=2,272). Drug-coated balloon (DCB) vs. Drug-eluting stent (DES) was evaluated on 2-year device-oriented composite endpoint (DoCE) (HR 3.82, 95% CI 1.64-8.87, p=0.002). Drug-coated balloons were associated with a higher risk of 2-year device-oriented composite endpoint compared to drug-eluting stents in patients undergoing de novo, non-complex percutaneous coronary intervention, irrespective of pulse pressure levels.
Synapse has enriched 10 related papers. Consider them for comparative context: